Thermo Fisher Scientific Announces Offering of Senior Notes
WALTHAM, Mass. -- December 4, 2013
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving
science, announced today that it intends to offer senior notes to fund a
portion of its acquisition of Life Technologies Corporation. On April 15,
2013, the company announced its agreement to acquire Life Technologies for an
aggregate purchase price of approximately $13.6 billion.
The joint book-running managers for the offering are Barclays Capital Inc.,
J.P. Morgan Securities LLC and RBS Securities Inc.
Thermo Fisher has filed a registration statement on Form S-3 (including a
prospectus) with the Securities and Exchange Commission (the “SEC”) for this
offering. Prospective investors should read the prospectus forming a part of
that registration statement and the preliminary prospectus supplement related
to the offering and the other documents that the company has filed with the
SEC for more complete information about the company and this offering. These
documents are available at no charge by visiting EDGAR on the SEC website at
www.sec.gov. Alternatively, these documents will be made available upon
request by the company or by any underwriter or dealer participating in the
offering. Interested parties may obtain a prospectus or the related
preliminary prospectus supplement from Barclays Capital Inc. by directing a
request to Barclays Capital Inc. c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, by writing
email@example.com or by calling 1-888-603-5847; from J.P.
Morgan Securities LLC by directing a request to J.P. Morgan Securities LLC,
383 Madison Avenue, New York, NY 10179, Attn: Investment Grade Syndicate Desk
- 3rd Floor, or by calling 212-834-4533; or from RBS Securities Inc. by
directing a request to RBS Securities Inc., 600 Washington Boulevard,
Stamford, CT 06901, Attn: Syndicate, or by calling 866-884-2071.
This press release shall not constitute an offer to sell or the solicitation
of an offer to buy the notes, nor shall there be any offer, solicitation or
sale of the notes in any jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification under the
securities laws of any such jurisdiction.
Thermo Fisher Scientific Inc.
Ron O’Brien, 781-622-1242
Ken Apicerno, 781-622-1294
Press spacebar to pause and continue. Press esc to stop.